Clinical Trial Details
| Trial ID: | L4105 |
| Source ID: | NCT00455858 |
| Associated Drug: | Insulin Detemir |
| Title: | Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT00455858/results |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: insulin detemir |
| Outcome Measures: | Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20, Change in Glycosylated Haemoglobin A1c (HbA1c) from baseline to week 20, week 0, week 20 | Secondary: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 12, Change in Glycosylated Haemoglobin A1c (HbA1c) at week 12 from baseline, week 0, week 12|Change in Fasting Plasma Glucose (FPG), Change in fasting plasma glucose (FPG) from baseline to week 12 and week 20, week 0, week 12, week 20|Percentage of Subjects Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7.0%, Percentage (%) of subjects achieving Glycosylated Haemoglobin A1c (HbA1c) treatment target levels less than 7.0%, week 12, week 20|Occurence of Hypoglycaemic Episodes, Occurence of hypoglycaemic episodes - diurnal and nocturnal - over 20 weeks of treatment., weeks 0-20 |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 87 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2007-11 |
| Completion Date: | 2008-10 |
| Results First Posted: | 2010-02-23 |
| Last Update Posted: | 2024-02-01 |
| Locations: | Seoul, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT00455858 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|